Tris DBA significantly inhibited tumor growth in xenograft MM and orthotopic HCC preclinical mice models with a reduction in the expression of various prosurvival biomarkers in MM tumor tissues without displaying significant toxicity. Overall, Tris DBA functions as a good inhibitor of STAT3 signaling in preclinical HCC and MM models.

almost 3 years ago

Preclinical • Journal

JAK2 (Janus kinase 2) • IL6 (Interleukin 6) • JAK1 (Janus Kinase 1)

STAT3 expression

tris DBA palladium (Tris DBA)

4years

Tris DBA ameliorates IgA nephropathy by blunting the activating signal of NLRP3 inflammasome through SIRT1- and SIRT3-mediated autophagy induction. (PubMed, J Cell Mol Med)

In conclusion, Tris DBA effectively ameliorated the mouse IgAN model and targeted signalling pathways downstream of ICs-mediated interaction, which is a novel immunomodulatory strategy. Further development of Tris DBA as a therapeutic candidate for IgAN is warranted.

4 years ago

Journal

SIRT1 (Sirtuin 1)

tris DBA palladium (Tris DBA)

4years

Palladium based nanoparticles for the treatment of advanced melanoma. (PubMed, Sci Rep)

Surprisingly, the HANP containing IGF1R antibody was less effective than particles without antibody, possibly due to steric hindrance of IGF1R and CD44 binding. Tris DBA-Pd nanoparticles are an effective therapy for CD44-positive tumors like melanoma, and further development of these nanoparticles should be pursued.

4 years ago

Journal

BRAF (B-raf proto-oncogene) • IGF1R (Insulin-like growth factor 1 receptor) • CD44 (CD44 Molecule)

BRAF mutation

tris DBA palladium (Tris DBA)